$2.85 Billion is the total value of Camber Capital Management LP's 33 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CHNG | Sell | CHANGE HEALTHCARE INC | $242,450,000 | -44.3% | 13,000,000 | -56.7% | 8.51% | -25.9% |
| VTRS | New | VIATRIS INC | $224,880,000 | – | 12,000,000 | +100.0% | 7.89% | – |
| UHS | Sell | UNIVERSAL HLTH SVCS INCcl b | $192,500,000 | -21.8% | 1,400,000 | -39.1% | 6.76% | +4.1% |
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $183,582,000 | -38.3% | 1,175,000 | -54.8% | 6.44% | -17.9% |
| GILD | New | GILEAD SCIENCES INCcall | $145,650,000 | – | 2,500,000 | +100.0% | 5.11% | – |
| HCA | Sell | HCA HEALTHCARE INC | $139,791,000 | -22.7% | 850,000 | -41.4% | 4.91% | +2.9% |
| ALKS | Sell | ALKERMES PLC | $134,663,000 | -44.0% | 6,750,000 | -53.4% | 4.73% | -25.4% |
| PRGO | Sell | PERRIGO CO PLC | $134,160,000 | -48.7% | 3,000,000 | -47.4% | 4.71% | -31.8% |
| GSK | Buy | GLAXOSMITHKLINE PLCsponsored adr | $128,800,000 | +280.2% | 3,500,000 | +288.9% | 4.52% | +406.3% |
| BMY | New | BRISTOL-MYERS SQUIBB COcall | $124,060,000 | – | 2,000,000 | +100.0% | 4.35% | – |
| THC | Buy | TENET HEALTHCARE CORP | $119,790,000 | +144.4% | 3,000,000 | +50.0% | 4.20% | +225.1% |
| WBA | New | WALGREENS BOOTS ALLIANCE INC | $119,640,000 | – | 3,000,000 | +100.0% | 4.20% | – |
| ABBV | New | ABBVIE INCcall | $107,150,000 | – | 1,000,000 | +100.0% | 3.76% | – |
| MYGN | Sell | MYRIAD GENETICS INC | $98,875,000 | -24.2% | 5,000,000 | -50.0% | 3.47% | +0.9% |
| BHC | Sell | BAUSCH HEALTH COS INC | $88,400,000 | -36.8% | 4,250,000 | -52.8% | 3.10% | -15.9% |
| IRWD | Sell | IRONWOOD PHARMACEUTICALS INC | $85,425,000 | -34.5% | 7,500,000 | -48.3% | 3.00% | -12.8% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $68,196,000 | -42.9% | 400,000 | -52.9% | 2.39% | -24.0% |
| BKD | Sell | BROOKDALE SR LIVING INC | $54,046,000 | -29.1% | 12,200,000 | -59.3% | 1.90% | -5.6% |
| BIIB | New | BIOGEN INC | $48,972,000 | – | 200,000 | +100.0% | 1.72% | – |
| AVRO | Sell | AVROBIO INC | $43,679,000 | -6.8% | 3,133,333 | -13.0% | 1.53% | +24.0% |
| TEVA | Sell | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $43,425,000 | -46.4% | 4,500,000 | -50.0% | 1.52% | -28.8% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $42,500,000 | -48.8% | 2,500,000 | -50.0% | 1.49% | -31.8% |
| COLL | Sell | COLLEGIUM PHARMACEUTICAL INC | $40,060,000 | -51.9% | 2,000,000 | -50.0% | 1.41% | -36.0% |
| WBA | New | WALGREENS BOOTS ALLIANCE INCcall | $39,880,000 | – | 1,000,000 | +100.0% | 1.40% | – |
| CHRS | Sell | COHERUS BIOSCIENCES INC | $38,236,000 | -52.6% | 2,200,000 | -50.0% | 1.34% | -36.9% |
| RDUS | Sell | RADIUS HEALTH INC | $37,060,000 | -21.3% | 2,075,000 | -50.0% | 1.30% | +4.8% |
| BLUE | Sell | BLUEBIRD BIO INC | $34,616,000 | -70.8% | 800,000 | -63.6% | 1.22% | -61.2% |
| OSUR | Sell | ORASURE TECHNOLOGIES INC | $34,401,000 | -48.6% | 3,250,000 | -40.9% | 1.21% | -31.6% |
| PBYI | Sell | PUMA BIOTECHNOLOGY INC | $26,214,000 | -49.2% | 2,555,000 | -50.0% | 0.92% | -32.4% |
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $11,566,000 | -38.8% | 525,000 | -50.0% | 0.41% | -18.5% |
| ANGO | Buy | ANGIODYNAMICS INC | $8,284,000 | +1543.7% | 540,362 | +1194.2% | 0.29% | +2138.5% |
| GLYC | Sell | GLYCOMIMETICS INC | $8,272,000 | -46.1% | 2,200,000 | -56.0% | 0.29% | -28.4% |
| VIR | Exit | VIR BIOTECHNOLOGY INC | $0 | – | -16,464 | -100.0% | -0.02% | – |
| VIRC | Exit | VIRCO MFG CO | $0 | – | -16,464 | -100.0% | -0.02% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -100,000 | -100.0% | -0.14% | – |
| STRO | Exit | SUTRO BIOPHARMA INC | $0 | – | -1,200,000 | -100.0% | -0.32% | – |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -877,600 | -100.0% | -0.81% | – |
| ATRA | Exit | ATARA BIOTHERAPEUTICS INC | $0 | – | -2,800,000 | -100.0% | -0.96% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -800,000 | -100.0% | -1.60% | – |
| AMAG | Exit | AMAG PHARMACEUTICALS INC | $0 | – | -8,780,000 | -100.0% | -2.18% | – |
| CI | Exit | CIGNA CORP NEW | $0 | – | -500,000 | -100.0% | -2.23% | – |
| Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -8,820,000 | -100.0% | -2.30% | – | |
| MYL | Exit | MYLAN N V | $0 | – | -24,000,000 | -100.0% | -9.39% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.